Af­ter FDA re­vokes EUA for GSK-part­nered mAb, Vir changes its plans on Covid-19 treat­ments

Vir Biotech­nol­o­gy is mov­ing away from some of its Covid-19 am­bi­tions.

Months af­ter the FDA re­voked the emer­gency use au­tho­riza­tion on Vir and GSK’s mon­o­clon­al …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER